Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>US drug regulator approves the use of <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">Remdesivir</keyword> for treating hospitalised COVID-19 patients.</li><li>The US FDA said Veklury (the drug's brand name) cuts the recovery time on average by five days during clinical trials.</li><li>Cipla, Zydus Cadila, Dr Reddy’s are some of the companies that have launched the generic drug Remdesivir in India</li><li>Remdesivir has received much criticism from experts over its effectiveness. A WHO Solidarity trial found that the drug failed to reduce the mortality or hospital stay of the patients.</li></ul>The shares of pharma major Cipla, Zydus Cadila, Jubilant Life Sciences and Dr Reddy Labs gained during the early trading hours on Friday after the US Food and Drug Administration (FDA) approved the use of antiviral drug Remdesivir to treat COVID-19 patients in hospitals. The US FDA has said Veklury (drug's brand name) cut the recovery time on average by five days during clinical trials. "Veklury is the first treatment for COVID-19 to receive FDA approval," the FDA said in a statement. The Remdesivir boost <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Share price change on Oct 23* </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Share price change since June 30 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">21.20% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">28% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">20% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jubilant Life Sciences </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">14% </td></tr></tbody></table>*Share price change on Oct 23 till 10:35 am USFDA has approved the use of the drug for treatment of hospitalised COVID-19 patients — for adults and paediatric patients (12 years of age and older) and weighing at least 40 kilograms. The drug regulator’s decision was supported by the analysis of data from "three randomised, controlled clinical trials that included patients hospitalised with mild-to-severe Covid-19". Cipla, Zydus Cadila and Dr Reddy Laboratories are among the top drugmakers that have bagged the contract for the <a href="https://www.businessinsider.in/science/health/news/these-are-the-companies-that-are-making-remdesivir-in-india/articleshow/78030739.cms">manufacturing of Remdesivir in India</a>. These are the remdesivir drug manufacturers in India: <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdesivir Price </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2800 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero Labs </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5000-₹6000 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Redyx </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5400 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹4000 </td></tr></tbody></table> However not all experts are convinced of Remdesivir’s ‘effectiveness’ The Remdesivir COVID-19 vaccine has received much criticism from experts over its effectiveness. Even a WHO Solidarity trial examined the effects of remdesivir, and three other treatment candidates in more than 11,000 patients in 30 countries and the results from the clinical trial found that none of the drugs “substantially affected mortality,” reduced the need to ventilate patients or shortened hospital stays. “These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay,” the<a href="https://www.businessinsider.in/science/health/news/remdesivir-the-only-antiviral-authorized-for-covid-19-in-us-does-not-improve-chances-of-survival-a-massive-who-study-found/articleshow/78699732.cms"> report said</a>. SEE ALSO: <a href="https://www.businessinsider.in/india/news/trump-calls-india-china-and-russia-filthy-while-justifying-exit-from-paris-agreement/articleshow/78821267.cms" data-type="tilCustomLink">Trump calls India, China and Russia ‘filthy’ while justifying exit from Paris Agreement</a> <a href="https://www.businessinsider.in/science/health/news/gileads-remdesivir-just-got-the-first-fda-approval-to-be-used-as-a-treatment-for-coronavirus-patients/articleshow/78818920.cms" data-type="tilCustomLink">Gilead's remdesivir just got the first FDA approval to be used as a treatment for coronavirus patients</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-cipla-zydus-cadila-dr-reddy-laboratories-tech-mahindra-avenue-supermarts-cochin-shipyard-and-others/articleshow/78820314.cms" data-type="tilCustomLink">Top stocks to watch — Cipla, Zydus Cadila, Dr Reddy Laboratories, Tech Mahindra, Avenue Supermarts, Cochin Shipyard, and others</a>

Cipla, Zydus Cadila, Jubilant Life and Dr Reddy’s shares gain after FDA approves Remdesivir for treating COVID-19 patients

<ul><li>The 30-share BSE index Sensex was up 228 points, and the NSE Nifty rose 0.59% at 9:55 am. </li><li>Here’s a list of the top losers and gainers in the Nifty pack. </li><li>These are the top stocks that are buzzing in trade today.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian stock market indices opened on a higher note on Friday, tracking gains in index majors HDFC Bank, ICICI Bank and TCS amid positive cues from the global markets. The 30-share BSE index Sensex was up 228 points, and the NSE Nifty rose 0.59% at 9:55 am. Here’s a list of the top losers and gainers in the Nifty pack. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Gainers </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Losers </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tata Motors </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Shree Cement </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tata Steel </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">UltraTech Cement </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Adani Ports </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">GAIL </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Maruti </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HUL </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Power Grid </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">JSW Steel </td></tr></tbody></table>*as of October 23, 10:00 am These are the top stocks in news today. SBI Cards plunge over 10% The shares of SBI Cards opened nearly 10% lower after the company reported a 46% dip in its net profit to ₹206 crore for the second quarter ended September 30. Bad loans due to spike in loan defaults remained the concern with its gross non-performing assets (NPAs) rising to 4.3% compared to the same period last year. Bharti Infratel gains over 3% Bharti Infratel shares soared over 3% after the telecom infrastructure firm’s overall revenue grew by about 2% to ₹3,695 crore during the second quarter ended September 30. However, its consolidated net profit dropped 24% to ₹733 crore for the quarter. MphasiS up over 4% The shares of IT services company MphasiS gained over 4% after its gross revenue grew 12.9% YoY in the second quarter ended September 30. The company said its net profit grew 9.5% YoY to ₹299.2 crore. Biocon dips 1% post earnings The shares of Kiran Mazumdar-Shaw led biopharmaceutical company Biocon dipped over a percent after the company reported a 23.8% drop in its net profit to ₹200.40 crore. The profit plunge is despite the 11.33% growth in its total revenue to ₹1,744.80 crore. Zydus Cadila and Dr Reddy Laboratories up 1%, Cipla gains 2% The shares of Pharma major Cipla, Zydus Cadila and Dr Reddy Laboratories were trading in green during the early hours of market opening. The boost comes in after the US regulators have given full approval for the antiviral drug remdesivir to treat COVID-19 patients in hospitals. The US Food and Drug Administration (FDA) said Veklury, the drug's brand name, cut the recovery time on average by five days during clinical trials. Avenue Supermarts gains 1%, Cochin Shipyard leaps 5% The shares of India’s largest shipbuilding and maintenance company, Cochin Shipyard gained over 5% after the founder of Avenue Supermarts, Radhakishan Damani bought 0.5% equity stake in the company for ₹394.14 per share. Avenue Supermarts also gained nearly a percent post the announcement. SEE ALSO: <a href="https://www.businessinsider.in/india/news/trump-calls-india-china-and-russia-filthy-while-justifying-exit-from-paris-agreement/articleshow/78821267.cms" data-type="tilCustomLink">Trump calls India, China and Russia ‘filthy’ while justifying exit from Paris Agreement</a> <a href="https://www.businessinsider.in/science/health/news/gileads-remdesivir-just-got-the-first-fda-approval-to-be-used-as-a-treatment-for-coronavirus-patients/articleshow/78818920.cms" data-type="tilCustomLink">Gilead's remdesivir just got the first FDA approval to be used as a treatment for coronavirus patients</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-cipla-zydus-cadila-dr-reddy-laboratories-tech-mahindra-avenue-supermarts-cochin-shipyard-and-others/articleshow/78820314.cms" data-type="tilCustomLink">Top stocks to watch — Cipla, Zydus Cadila, Dr Reddy Laboratories, Tech Mahindra, Avenue Supermarts, Cochin Shipyard, and others</a>

Top stock movers — Tata Motors, SBI Cards,  Cochin Shipyard, Zydus Cadila, Cipla, Dr Reddy’s, MphasiS, and others

<ul><li>The SGX Nifty was trading 0.06% lower at 7:45 am, indicating a tepid opening for Nifty50. </li><li>Here’s a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider. </a></li></ul>Amidst mixed cues from the global markets, the Indian equities are likely to open flat on Friday. The SGX Nifty was trading 0.06% lower at 7:45 am, indicating a cautious opening for Nifty50. However, the US stocks closed higher on Thursday after Nancy Pelosi suggested that there has been progress and were ‘close’ to a stimulus deal. Dow Jones gained over 152 points, and the S&amp;P 500 ended 0.52% higher. These are the stocks to watch out for during the trading session on October 23: Tech Mahindra IT major Tech Mahindra’s US subsidiary will acquire 6.03% stake in US-based VitalTech Holdings, Inc for $3 million. The tentative date of closure of the transaction is October 26, it said in a regulatory filing. Tech Mahindra will also report its quarterly earnings today. The shares of Tech Mahindra ended 0.80% lower on Thursday. Cipla, Zydus Cadila, Dr Reddy Laboratories and other pharma companies The shares of Cipla, Zydus Cadila, Dr. Reddy Laboratories and other pharma companies will be in focus today. The US regulators have given full approval for the antiviral drug remdesivir to treat COVID-19 patients in hospitals. The US Food and Drug Administration (FDA) said Veklury, the drug's brand name, cut the recovery time on average by five days during clinical trials. HDFC AMC HDFC Asset Management Company has appointed KPMG as the internal auditor with immediate effect after Gautam Chandra, HDFC AMC’s former internal audit head resigned. The company also reported a 8% decline in profit after tax at ₹338.06 crore for the quarter ended September 30. The shares of HDFC AMC ended 1% higher on Thursday. Biocon Kiran Mazumdar-Shaw led biopharmaceutical company, Biocon reported a 23.8% drop in its net profit to ₹200.40 crore. This is despite 11.33% growth in its total revenue to ₹1,744.80 crore. The shares of Biocon ended 2.3% higher on Thursday. Avenue Supermarts and Cochin Shipyard The founder of Avenue Supermarts, Radhakishan Damani bought 0.5% equity stake in India’s largest shipbuilding and maintenance company, Cochin Shipyard for ₹394.14 per share. The shares of Avenue Supermarts and Cochin Shipyard ended 2% and 9% higher on Thursday, respectively. Bharti Infratel Telecom infrastructure firm Bharti Airtel on Thursday posted a 24% drop in consolidated net profit to ₹733 crore for the quarter ended September 30. The overall revenue grew by about 2% to ₹3,695 crore during the reported quarter, the company said. The shares of Bharti Infratel ended 2% higher on Thursday. JSW Steel, Yes Bank, ICICI Lombard, Persistent Systems, Sudarshan Chemicals and IDBI Bank among others JSW Steel, Yes Bank, ICICI Lombard, Persistent Systems, Sudarshan Chemicals and IDBI Bank are the companies among others that are slated to report their quarterly earnings today. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/gileads-remdesivir-just-got-the-first-fda-approval-to-be-used-as-a-treatment-for-coronavirus-patients/articleshow/78818920.cms" data-type="tilCustomLink">Gilead's remdesivir just got the first FDA approval to be used as a treatment for coronavirus patients</a> <a href="https://www.businessinsider.in/tech/news/social-media-will-change-when-users-ask-for-their-cut-from-data-revenue/articleshow/78810738.cms" data-type="tilCustomLink">‘Where’s my cut?’ the question that can revolutionise social media</a> <a href="https://www.businessinsider.in/business/startups/news/paytm-uses-jeff-bezos-secret-for-success-building-two-pizza-teams/articleshow/78810520.cms" data-type="tilCustomLink">EXCLUSIVE: Paytm uses Jeff Bezos' secret for success — building 'two pizza' teams</a>

Top stocks to watch — Cipla, Zydus Cadila, Dr Reddy Laboratories, Tech Mahindra, Avenue Supermarts, Cochin Shipyard, and others

<ul><li>The 30-share BSE index was trading 69 points lower, and NSE Nifty was trading flat at 12,977 points.</li><li>Here’s a list of the top losers and gainers in the Nifty pack. </li><li>These are the top stocks that are buzzing in trade today.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian equity benchmark indexes opened on a tepid note on Friday, tracking subdued cues from global markets. The 30-share BSE index was trading 69 points lower, and NSE Nifty was trading flat at 12,977 points. Here’s a list of the top losers and gainers in the Nifty pack. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Gainers </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Losers </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tata Motors </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HDFC Life </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Bajaj Auto </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Power Grid </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">NTPC </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">TCS </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Britannia </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HDFC </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">GAIL </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">SBI </td></tr></tbody></table>*as of November 27, 10:10 am These are the top stocks in news today. AstraZeneca Pharma India down nearly a percent AstraZeneca Pharma India trades in red after <a href="https://www.businessinsider.in/science/news/astrazeneca-will-likely-re-test-its-covid-19-vaccine-ceo-says-after-admitting-an-error-in-the-first-trial-that-may-have-skewed-results/articleshow/79434619.cms">AstraZeneca CEO</a> said it is likely to retest its COVID-19 vaccine after an error in the first trial that may have skewed results. Zydus Cadila trades 6% higher The shares of Zydus Cadila soared nearly 6% after the <a href="https://m.economictimes.com/industry/healthcare/biotech/zydus-cadila-to-apply-for-phase-3-trials-in-december-hopes-to-launch-vaccine-by-march/amp_articleshow/79437944.cms">news reports</a> surfaced that the company aims to apply for phase-3 trials in December and will launch the vaccine by March if it works out. Future Retail locked in 5% lower circuit for the second day The shares of Future Retail (FRL) were locked in a 5% lower circuit for the second day in a row. In a <a href="https://www.businessinsider.in/stock-market/news/future-retail-tells-the-bourses-that-not-every-stage-of-the-amazon-proceedings-would-be-material-event-for-disclosure/articleshow/79438955.cms">recent development,</a> Future Retail has informed the bourses that with Amazon taking the case back to Singapore court, not every stage of the proceeding is a “material event for disclosure.” Earlier this week, the National Stock Exchange (NSE) had warned FRL that it risked regulatory action for not making timely disclosures about the legal battle with Amazon over the disputed asset sale. DHFL locked in 5% upper circuit The shares of debt-ridden DHFL were locked in a 5% upper circuit for the ninth day in a row — hitting the 52-week high— after the company trimmed down its losses in the second quarter. Mahindra &amp; Mahindra trades over a percent higher Mahindra &amp; Mahindra’s (M&amp;M) gained over a percent after its wholly-owned subsidiary, Mahindra Holdings (MHL) has decided to sell its 100% stake of Mahindra First Choice Services (MFCS) and Auto Digitech (ADPL) to TVS Automobile Solutions (TASL). Indraprastha Gas, Gujarat Gas, Mahanagar Gas and other gas distribution stocks rally The shares of Indraprastha Gas, Gujarat Gas, Mahanagar Gas and other gas distribution stocks rallied over 10% after oil regulator Petroleum and Natural Gas Regulatory Board (PNGRB) notified regulations for unified gas transmission tariff structure. The tariffs will be applicable based on two-zone structure related to distance from the source of gas. Indraprastha Gas was trading 13% higher, Gujarat Gas was up 6%, and Mahanagar Gas gained nearly 12%. SEE ALSO: <a href="https://www.businessinsider.in/business/auto/news/checkout-top-electric-cars-price-from-delhi-mumbai-chennai-bengaluru-kolkata/articleshow/79429631.cms" data-type="tilCustomLink">From Tata Nexon EV and MG ZS EV to Hyundai Kona Electric — here’s how much top electric cars cost in India</a> <a href="https://www.businessinsider.in/science/news/astrazeneca-will-likely-re-test-its-covid-19-vaccine-ceo-says-after-admitting-an-error-in-the-first-trial-that-may-have-skewed-results/articleshow/79434619.cms" data-type="tilCustomLink">AstraZeneca will likely retest its COVID-19 vaccine, CEO says after admitting an error in the first trial that may have skewed results</a>

Top stock movers — Future Retail, AstraZeneca, Cadila, DHFL, M&M, Indraprastha Gas, Gujarat Gas, Mahanagar Gas, and others

New Delhi, Dec 11 () Drug firm Zydus Cadila on Wednesday said it has launched its affordable oral anti-diabetic Vinglyn brand tablets available in two formulations in India.
 As the product patent on popular diabetes drug Vildagliptin has expired in India on December 9, some domestic drug firms have launched the generic versions of the drug in the country that are much cheaper than the patented medicine.
 "Priced at just Rs 4.95 per tablet, which is almost 1/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India," Zydus Cadila said in a statement.
 Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd, it added.
 Zydus Cadila Managing Director Sharvil Patel said, "Fortifying our fight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society."
 With Vinglyn, Zydus Cadila believes that it has once again been able to offer this. The access to one of the most affordable gliptin therapies will help a large number of patients suffering from type-2 diabetes, in India, he added.
 With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.
 The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management, the statement said.
 Another drug firm Panacea Biotec on Tuesday had said it had launched its VilACT brand tablets available in four formulations, for treatment of type-2 diabetes in India.
 The company had also said its brand will be an affordable and high-quality medicine.
 According to the AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs 969 crore and is growing at the rate of 4 per cent, Panacea Biotec had said.
 Shares of Cadila Healthcare, the listed entity of the Zydus group closed at Rs 262.25 per scrip on the BSE, up 0.50 per cent from its previous close. AKT HRS

Zydus Cadila launches affordable oral anti-diabetic tablets in India as drug goes off patent

<ul><li>The SGX Nifty was trading 0.62% higher at 7:45 am, indicating a higher start for Nifty50.</li><li>Here’s a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider. </a></li></ul>Amidst positive cues from the global markets, the Indian equities are likely to open higher on Tuesday. The SGX Nifty was trading 0.62% higher at 7:45 am, indicating a green start for Nifty50. The US stock markets also soared on Monday, as encouraging economic data and election bets lifted indexes. The Dow Jones Industrial Average closed 423 points higher, and the S&amp;P 500 gained 1.23%. These are the stocks to watch out for during the trading session on November 3: Tata Motors Auto giant Tata Motors reported a 27% jump in its total domestic sales to 49,669 units in October. The passenger vehicle segment grew 80%, whereas the commercial vehicle segment witnessed a marginal growth at 2%. The shares of Tata Motors ended flat on Tuesday. Cadila Healthcare The drug major Cadila Healthcare reported an over four-fold jump in its consolidated net profit to ₹473.4 crore for the quarter ended September 30. The company had posted a net profit of ₹107.2 crore for the corresponding period of the previous financial year. The company has significantly reduced its net debt-by ₹2,709 crore in the first six months of FY21, which is a 40% reduction from net debt reported in March 2020. The shares of Cadila Healthcare ended 3% lower on Tuesday. NTPC The board of state-owned power giant NTPC has approved the buyback of 19.78 crore equity shares at a price of ₹115 per unit for an aggregate amount of ₹2,275.74 crore. The company has fixed November 13 as the record date for the purpose of ascertaining the eligibility of shareholders for buyback of equity shares. The shares of NTPC ended 2.23% higher on Tuesday. Sterlite Tech The fiber optic cable manufacturing company, Sterlite Tech said it would acquire Italy’s Optotec S.p.A., a company specializing in optical interconnect products, for €29 million. The company said that the acquisition would create a solid springboard to offer a complete bouquet of solutions to customers across Europe, India and the Middle East. The shares of Sterlite Tech ended 2% lower on Tuesday. Adani Enterprises The Airports Authority of India (AAI) handed over the Lucknow airport to the Adani group on lease for a period of 50 years. The AAI had signed concession agreements with the Adani group on February 14 for operations, management and development of the Mangaluru, Lucknow and Ahmedabad airports. The shares of Adani Enterprises ended 0.16% higher on Tuesday. Shipping Corporation of India The board of the Shipping Corporation of India is slated to meet on November 6 to discuss the demerger of non-core assets. The shares of Shipping Corporation of India ended 2% lower on Tuesday. Nagarjuna Construction Company Nagarjuna Construction Company (NCC) bagged orders worth ₹833 crore from the mining division of Coal India’s arm. The shares of Nagarjuna Construction Company ended 1% lower on Tuesday. Muthoot Finance, PVR, Sun Pharmaceutical Industries, Dabur and Adani Ports Muthoot Finance, PVR, Sun Pharmaceutical Industries, Dabur and Adani Ports are the top companies slated to report their quarterly earnings today. SEE ALSO: <a href="https://www.businessinsider.in/international/news/multiple-casualties-reported-in-vienna-terrorist-attack-officials-say/articleshow/79009954.cms">At least 2 people dead and more than a dozen injured in Vienna terror attack</a> <a href="https://www.businessinsider.in/politics/world/news/how-the-electoral-college-works-and-how-the-president-will-be-selected-this-year/articleshow/77745886.cms">How the electoral college works and how the president will be selected this year</a>

Top stocks to watch — Tata Motors, NTPC, Cadila Healthcare, Adani Enterprises, Muthoot Finance, Dabur, and others

<ul><li>At 8:30 am, SGX Nifty was up by 50 points, or 0.37%. </li><li>Here’s a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian stock markets could extend their gains on Monday after the Nifty crossed the 13,700 level on Thursday last week. At 8:30 am, SGX Nifty was up by 50 points, or 0.37%, suggesting that the Indian stock exchanges could have a positive start to the day. With the <a href="https://www.businessinsider.in/politics/world/news/trump-signs-bipartisan-coronavirus-relief-bill-after-calling-on-congress-to-approve-2000-stimulus-checks/articleshow/79984320.cms">Trump administration signing the $2,000 stimulus relief cheques</a> with bipartisan support, the US stock exchanges could bounce back. These are the stocks to watch out for during the trading session today: Reliance Industries Reliance Industries is all set to buy IMG Worldwide’s 50% stake in IMG-Reliance for ₹52.08 crore in a cash deal. IMG is a global sports, events, and talent management company. <keyword id="45383" type="DOMAIN" weightage="20" keywordseo="Coal-India">Coal India</keyword> The Maharatna public sector undertaking Coal India’s board has approved the company’s entry into aluminum and solar power sectors. Special purpose vehicles will be created in this regard. <keyword id="46698" type="DOMAIN" weightage="20" keywordseo="Lupin">Lupin</keyword> Lupin has received tentative approval from the US FDA for the generic version of Jublia solution. This solution is a prescription for treating toenail fungus. <keyword id="6362997" type="LOCATION" weightage="20" keywordseo="dlf">DLF</keyword> DLF Cyber City will acquire the stake of its partner Hines in One Horizon Center for ₹780 crore. The One Horizon Center is a 25-storied building located in Gurugram, Haryana. <keyword id="1350" type="CITY" weightage="20" keywordseo="Niit">NIIT</keyword> NIIT’s board has approved a share buyback proposal. Accordingly, the company will buyback shares worth ₹237 crore at a price of ₹240 per equity share. This is a premium of 20% compared to the closing price of ₹200.40 on December 24. Reliance Capital The troubled Reliance Capital has announced that it has defaulted on term loans from HDFC and Axis Bank. <keyword id="6362804" type="DOMAIN" weightage="20" keywordseo="cadila">Cadila</keyword> Healthcare Zydus Cadila Healthcare has announced that its COVID-19 vaccine, ZyCoV-D was found to be safe, well-tolerated during the Phase I and II clinical trials. It is now planning to begin Phase III trials with 30,000 volunteers after obtaining the required approvals. <keyword id="51758" type="DOMAIN" weightage="20" keywordseo="Dish-TV">Dish TV</keyword> Dish TV has received a demand notice from the government for the payment of license fee and interest to the tune of ₹4,164 crore. <keyword id="28423" type="DOMAIN" weightage="20" keywordseo="vedanta">Vedanta</keyword> Vedanta’s parent company, Vedanta Resources has increased its stake in the Indian unit to 55.11% by acquiring shares worth almost ₹3,000 crore from the open market. SEE ALSO: <a href="https://www.businessinsider.in/politics/world/news/trump-signs-bipartisan-coronavirus-relief-bill-after-calling-on-congress-to-approve-2000-stimulus-checks/articleshow/79984320.cms">Trump signs bipartisan coronavirus relief bill after calling on Congress to approve $2,000 stimulus checks</a> <a href="https://www.businessinsider.in/stock-market/news/new-fiscal-support-will-set-up-an-economic-boom-in-the-second-half-of-2021-evercore-analysts-say/articleshow/79978963.cms">New fiscal support will set up an economic boom in the second half of 2021, Evercore analysts say</a> <a href="https://www.businessinsider.in/stock-market/news/insiders-cash-out-via-ipos-as-investor-optimism-becomes-excessive-ndr-says/articleshow/79968643.cms">Insiders cash out via IPOs as investor optimism becomes excessive, NDR says</a>

Top stocks to watch – RIL, Coal India, Lupin, DLF, NIIT, Reliance Capital, Cadila Health, Dish TV, Vedanta, and others

<ul><li>The Indian stock markets could open on a positive note on September 21, after experiencing a bear hug on the previous day. </li><li>Trends on SGX <keyword id="6354813" type="General" weightage="20" keywordseo="nifty" source="Orion">Nifty</keyword> showed an increase of 47 points, suggesting that Nifty could open in the green amid negative cues in other Asian markets. </li><li>SBI Cards, Adani Ports and HCL Tech could be among the top stocks to watch out for on September 21. </li></ul><cmsannotation type="cmsannotation" annotationid="SBI Card &amp; Payment Services" comment="subhead" text="SBI Card &amp; Payment Services">SBI Card &amp; Payment Services</cmsannotation> US-based private equity firm The Carlyle Group is planning to sell a 3.4 percent stake in the company, valued at ₹3,267 crore, in the price range of ₹1,021 to ₹1,072 per share. <cmsannotation type="cmsannotation" annotationid="Adani Ports &amp; SEZ" comment="subhead" text="Adani Ports &amp; SEZ">Adani Ports &amp; SEZ</cmsannotation> Received approval from the Competition Commission of India to acquire a 10.4 percent stake in the Gangavaram Port project in Andhra Pradesh. <cmsannotation type="cmsannotation" annotationid="HCL Tech" comment="subhead" text="HCL Tech">HCL Tech</cmsannotation> Bagged a digital transformation order from US-based MKS Instruments Inc., for five years. <cmsannotation type="cmsannotation" annotationid="IPO Watch" comment="subhead" text="IPO Watch">IPO Watch</cmsannotation> Paras Defence and Space Technologies IPO worth ₹171 crore to kick off today, with a price band of ₹165-175 per share. <cmsannotation type="cmsannotation" annotationid="Cadila Healthcare" comment="subhead" text="Cadila Healthcare">Cadila Healthcare</cmsannotation> Its subsidiary has entered into an agreement with Integrace to sell two brands, Mifegest and Cytolog. <cmsannotation type="cmsannotation" annotationid="Kitex Garments" comment="subhead" text="Kitex Garments">Kitex Garments</cmsannotation> Entered into a memorandum of understanding with the Telangana government to invest ₹2,406 crore in the state. <cmsannotation type="cmsannotation" annotationid="Yes Bank" comment="subhead" text="Yes Bank">Yes Bank</cmsannotation> Partnered with Visa to offer credit cards to its customers after the ban on MasterCard. <cmsannotation type="cmsannotation" annotationid="Nestle India" comment="subhead" text="Nestle India">Nestle India</cmsannotation> Reports suggest that the company’s chairman has revealed that it may face headwinds in 2022 due to rising coffee prices globally. <cmsannotation type="cmsannotation" annotationid="Action Construction Equipment" comment="subhead" text="Action Construction Equipment">Action Construction Equipment</cmsannotation> Launched its qualified institutional placement on Monday, with the price band fixed at ₹254.55 per equity share. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/how-to-check-allotment-status-for-sansera-engineering-ipo/articleshow/86380353.cms">Sansera Engineering IPO — How to check allotment status, listing date and more</a> <a href="https://www.businessinsider.in/tech/mobile/news/samsung-galaxy-z-fold-3-foldable-smartphone-review/articleshow/86366351.cms">Samsung Galaxy Z Fold 3 review: Creasing through the folds</a> <a href="https://www.businessinsider.in/tech/news/emmys-2021-netflix-beats-hbo-for-the-first-time-with-the-most-number-of-awards/articleshow/86365603.cms">Emmys 2021: Netflix beats HBO for the first time with the most number of awards</a>

SBI Cards, Adani Ports, HCL Tech and other top stocks to watch out for on September 21

Mumbai, Jul 3 () The rupee appreciated 44 paise to 74.60 against the US dollar in early trade on Friday tracking weakness in the greenback and gains in the domestic equity market amid optimism over potential COVID-19 vaccine. Forex traders said investors were bullish on emerging market assets following encouraging vaccine test results. Moreover, positive domestic equities, steady crude oil prices and weak US currency supported the local unit. The rupee opened at 74.60 against the US dollar, registering a jump of 44 paise over its previous close. It had settled at 75.04 against the greenback on Thursday. A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials. The approval process was fast-tracked following recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic. Meanwhile, the dollar index, which gauges the greenback's strength against a basket of six currencies, fell 0.04 per cent to 97.27. On the domestic equity market front, the 30-share BSE benchmark Sensex was trading 151.64 points higher at 35,995.34 and broader NSE Nifty rose 50.60 points to 10,602.30. Foreign institutional investors were net sellers in the capital market as they sold shares worth Rs 556.72 crore on Thursday, according to provisional exchange data. Brent crude futures, the global oil benchmark, fell 0.90 per cent to USD 42.75 per barrel. Meanwhile, the number of cases around the world linked to COVID-19 has crossed 1.08 crore and the death toll has topped 5.20 lakh. In India, the death toll due the disease rose to 18,213 and the number of infections spiked to 6,25,544, according to the health ministry. DRR ANS ANS

Rupee jumps 44 paise to 74.60 against US dollar in early trade

Mumbai, Jul 3 () The rupee appreciated 38 paise to settle at 74.66 against the US dollar on Friday tracking weakness in the greenback and gains in the domestic equity market amid optimism over potential COVID-19 vaccine. Forex traders said investors were bullish on emerging market assets following encouraging vaccine test results. Moreover, positive domestic equities, steady crude oil prices and weak US currency supported the local unit. The rupee opened at 74.60, and settled for the day at 74.66 against the US dollar, registering a jump of 38 paise over its previous close. It had settled at 75.04 against the greenback on Thursday. During the four-hour trading session, the rupee witnessed an intra-day high of 74.60 and a low of 75.02. A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare has got approval from the Drugs Controller General of India (DCGI) for human clinical trials. The approval process was fast-tracked following recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic. The dollar index, which gauges the greenback's strength against a basket of six currencies, fell 0.11 per cent to 97.20. On the domestic equity market front, the 30-share BSE benchmark Sensex was trading 145.54 points higher at 35,989.24 and broader NSE Nifty rose 45.30 points to 10,597.00. Foreign institutional investors were net sellers in the capital market as they sold shares worth Rs 556.72 crore on Thursday, according to provisional exchange data. Brent crude futures, the global oil benchmark, fell 1.11 per cent to USD 42.66 per barrel. Meanwhile, the number of cases around the world linked to COVID-19 has crossed 1.08 crore and the death toll has topped 5.20 lakh. In India, the death toll due the disease rose to 18,213 and the number of infections spiked to 6,25,544, according to the health ministry. DRR ANS ANS

You Searched For "cadila share price" and got 10 results

Cipla, Zydus Cadila, Jubilant Life and Dr Reddy’s shares gain after FDA approves Remdesivir for treating COVID-19 patients

Navdeep Yadav

Top stock movers — Tata Motors, SBI Cards, Cochin Shipyard, Zydus Cadila, Cipla, Dr Reddy’s, MphasiS, and others

Navdeep Yadav

Top stocks to watch — Cipla, Zydus Cadila, Dr Reddy Laboratories, Tech Mahindra, Avenue Supermarts, Cochin Shipyard, and others

Navdeep Yadav

Top stock movers — Future Retail, AstraZeneca, Cadila, DHFL, M&M, Indraprastha Gas, Gujarat Gas, Mahanagar Gas, and others

Navdeep Yadav

Zydus Cadila launches affordable oral anti-diabetic tablets in India as drug goes off patent

PTI

Top stocks to watch — Tata Motors, NTPC, Cadila Healthcare, Adani Enterprises, Muthoot Finance, Dabur, and others

Navdeep Yadav

Top stocks to watch – RIL, Coal India, Lupin, DLF, NIIT, Reliance Capital, Cadila Health, Dish TV, Vedanta, and others

Rounak Jain

SBI Cards, Adani Ports, HCL Tech and other top stocks to watch out for on September 21

Rounak Jain

Rupee jumps 44 paise to 74.60 against US dollar in early trade

PTI

Rupee jumps 38 paise to close at 74.66 against US dollar

PTI

Popular Keywords

Buying Guides